Can-Fite BioPharma (NYSE:CANF) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANFGet Rating) in a research report issued on Friday. The firm set a “sell” rating on the stock.

NYSE CANF opened at $0.83 on Friday. The company has a market capitalization of $22.54 million, a price-to-earnings ratio of -1.20 and a beta of 1.86. Can-Fite BioPharma has a 52 week low of $0.78 and a 52 week high of $2.62.

Can-Fite BioPharma Company Profile (Get Rating)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.

Recommended Stories

Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.